Alnylam Pharmaceuticals, Inc., 10% Owner at Regulus Therapeutics Inc. (RGLS), sold 1,000,000 shares at $7.18 ($7.2M) on 2016-02-23, disclosed to the SEC on 2016-02-24.
Open-market sale of $7.2M RGLS by 10% Owner. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| RGLS | SELL | 2014-10-17 | $81K | — | Filing → |
| RGLS | SELL | 2014-10-10 | $66K | — | Filing → |
| RGLS | SELL | 2014-10-03 | $69K | — | Filing → |